Pure Global
NCT05626270

Human Factors Testing for OTC Use of the Erchonia® LunulaLaser

Human Factors Validation Testing for Over-the-Counter Use of the Erchonia® LunulaLaser™ OTC
Erchonia Corporation·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Onychomycosis
Drug/Device/Intervention
LunulaLaser OTC
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Erchonia Corporation
Location
Melbourne, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jun 04, 2021
End date
Dec 23, 2022
Enrollment
15 participants
Primary outcome

Human Factors

Summary

Human factors validation testing to assess the intended user's ability to correctly, safely,
 and effectively set-up, activate and operate the LunulaLaser™ OTC, to administer a treatment
 to a suitably qualified client, and to understand the information contained in the Erchonia
 LunulaLaser™ OTC Installation and Proper Use Reference Guide and box labeling.

ICD-10 classifications
OnychogryphosisChromomycosis, unspecifiedOnycholysisActinomycosisBlastomycosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05626270
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05626270 through Pure Global AI's free database. This phase not specified trial is sponsored by Erchonia Corporation and is currently Completed. The study focuses on Onychomycosis. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.